Novo Nordisk prepares to launch diabetes tablet in India
Rybelsus may be accessible for diabetes patients in India from 2022 onwards, states Novo Nordisk.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk has set its sights on India's large group of diabetes patients as a future market for the treatment Rybelsus, which is the tablet-based form of the Danish pharmaceutical company's newest diabetes treatment semaglutide.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings co-leads Swiss funding round
For subscribers
